RAPA113 + clopidogrel

RAPA113 + clopidogrel is a fixed-dose oral combination of two small molecule drugs: **RAPA113** and **clopidogrel**. RAPA113 is an investigational small molecule drug; detailed pharmacologic properties and mechanism of action are not disclosed in public sources, but it is being evaluated for potential drug-drug interaction effects with clopidogrel. **Clopidogrel** is an established antiplatelet agent that works as a P2Y12 receptor antagonist, inhibiting ADP-mediated platelet aggregation and used to prevent thrombotic cardiovascular events. The combination's investigational use is to assess whether co-administration of RAPA113 alters the pharmacodynamics or pharmacokinetics of clopidogrel, with possible implications for clinical safety and efficacy in settings where both agents might be co-prescribed. The combination has been studied in healthy volunteers in a Phase 1 crossover clinical trial.